InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.38
(
0.02%
)
US TECH 100
20,496.00
(
-0.10%
)
Dow Jones
43,958.19
(
0.11%
)
Brent Oil
71.81
(
0.27%
)
Bitcoin
89,534.01
(
1.83%
)
Post# of 253591
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12552
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: bladerunner1717 post# 224438

Wednesday, 04/03/2019 7:22:51 AM

Wednesday, April 03, 2019 7:22:51 AM

Post# of 253591
KURA- Bladerunner, KURA is very intriguing, except for this statement:

“Tipifarnib was previously studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets, ****however no molecular mechanism of action had previously been determined that could explain its activity across a range of diverse clinical indications****, including squamous tumors that carry mutant HRAS, as well as in lymphoid, myeloid and solid tumors that do not carry HRAS mutations. “

Without a discovered MOA, do they have a product???
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up